Literature DB >> 25981001

Hematopoietic stem cell transplantation for primary cutaneous γδ T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma.

Juliet Fraser Gibson1, Onder Alpdogan2, Antonio Subtil3, Michael Girardi4, Lynn D Wilson5, Kenneth Roberts5, Francine Foss6.   

Abstract

BACKGROUND: The panniculitic T-cell lymphomas (TCLs) comprise 2 distinct entities, αβ subcutaneous panniculitis-like TCL (SPTCL) and the γδ cutaneous TCLs with pannicular involvement primary cutaneous γδ (PCGD)-TCL. Although outcomes for most patients with SPTCL are favorable, those with PCGD-TCLs generally have an inferior outcome, and treatment strategies have not been well defined. Allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to be a potentially curative strategy in aggressive TCLs and in refractory and advanced-stage mycosis fungoides.
OBJECTIVE: We sought to analyze the outcomes of HSCT for panniculitic cutaneous TCL.
RESULTS: Fourteen patients (4 SPTCL, 10 PCGD-TCL) presented with primarily pannicular T-cell infiltrates. Seven patients underwent allogeneic HSCT from matched-related donors and matched-unrelated donors of which 4 (57%) are alive (1 SPTCL, 3 PCGD-TCL) at 7.8, 6.9, 6.2, and 0.25 years. Two patients underwent autologous HSCT (1 SPTCL, 1 PCGD-TCL) and both are alive at a median follow-up of 1.91 years. LIMITATIONS: This study is limited by its retrospective nature and small sample size because of the rarity of SPTCL and PCGD-TCL.
CONCLUSION: Aggressive therapy followed by allogeneic HSCT is a promising treatment modality for patients with PCGD-TCL.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T-cell lymphoma; hematopoietic stem cell transplantation; primary cutaneous γδ T-cell lymphoma; subcutaneous panniculitis-like T-cell lymphoma; γ-δ

Mesh:

Year:  2015        PMID: 25981001     DOI: 10.1016/j.jaad.2015.01.003

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

1.  Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas.

Authors:  Francine M Foss; Steven M Horwitz; Monica Civallero; Monica Bellei; Luigi Marcheselli; Won Seog Kim; Maria E Cabrera; Ivan Dlouhy; Arnon Nagler; Ranjana H Advani; Emanuela A Pesce; Young-Hyeh Ko; Silvia Montoto; Carlos Chiattone; Alison Moskowitz; Michele Spina; Marina Cesaretti; Irene Biasoli; Massimo Federico
Journal:  Am J Hematol       Date:  2019-11-25       Impact factor: 10.047

Review 2.  [Treatment of rare cutaneous T‑cell lymphoma and blastic plasmacytoid dendritic cell neoplasm].

Authors:  U Wehkamp; M Weichenthal
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

3.  Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine.

Authors:  Sophie Voruz; Laurence de Leval; Anne Cairoli
Journal:  Exp Hematol Oncol       Date:  2021-05-13

Review 4.  New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.

Authors:  Kazuyasu Fujii
Journal:  Front Oncol       Date:  2018-06-04       Impact factor: 6.244

Review 5.  Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas.

Authors:  Ibrahim N Muhsen; Riad El Fakih; Mehdi Hamadani; Hillard M Lazarus; Mohamed A Kharfan-Dabaja; Mahmoud Aljurf
Journal:  Clin Hematol Int       Date:  2022-06-22

6.  Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas.

Authors:  Jay Daniels; Peter G Doukas; Maria E Martinez Escala; Kimberly G Ringbloom; David J H Shih; Jingyi Yang; Kyle Tegtmeyer; Joonhee Park; Jane J Thomas; Mehmet E Selli; Can Altunbulakli; Ragul Gowthaman; Samuel H Mo; Balaji Jothishankar; David R Pease; Barbara Pro; Farah R Abdulla; Christopher Shea; Nidhi Sahni; Alejandro A Gru; Brian G Pierce; Abner Louissaint; Joan Guitart; Jaehyuk Choi
Journal:  Nat Commun       Date:  2020-04-14       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.